Chemoprevention by resveratrol and pterostilbene: Targeting on epigenetic regulation

BioFactors

Volumn 44, Issue 1, 2018, Pages 26-35

  Lee, Pei Sheng ^a   Chiou, Yi Shiou ^a   Ho, Chi Tang ^b   Pan, Min Hsiung ^a,c,d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b RUTGERS UNIVERSITY   (United States)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

Author keywords

chemoprevention; epigenetic; pterostilbene; resveratrol

Indexed keywords

MICRORNA; PTEROSTILBENE; RESVERATROL; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; HISTONE; STILBENE DERIVATIVE;

CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; DNA METHYLATION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION; GENE TARGETING; GENETIC REGULATION; HISTONE MODIFICATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; AGONISTS; ANTAGONISTS AND INHIBITORS; BONE DISEASE; CARDIOVASCULAR DISEASE; DEGENERATIVE DISEASE; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PROTEIN PROCESSING;

ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; BONE DISEASES; CARDIOVASCULAR DISEASES; CHEMOPREVENTION; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; MICRORNAS; NEOPLASMS; NEURODEGENERATIVE DISEASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; STILBENES;

EID: 85041443948     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1401     Document Type: Review

References (66)

1. Rimando, A. M., Cuendet, M., Desmarchelier, C., Mehta, R. G., Pezzuto, J. M., and Duke, S. O. (2002) Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. J. Agric. Food Chem., 50, 3453–3457.
2. Langcake, P., and Pryce, R. J. (1976) The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol. Plant Pathol., 9, 77–86.
3. Athar, M., Back, J. H., Kopelovich, L., Bickers, D. R., and Kim, A. L. (2009) Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch. Biochem. Biophys., 486, 95–102.
4. Baur, J. A., and Sinclair, D. A. (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov., 5, 493–506.
5. Cho, S., Namkoong, K., Shin, M., Park, J., Yang, E., et al. (2017) Cardiovascular protective effects and clinical applications of resveratrol. J. Med. Food, 20, 323–334.
6. Schmidlin, L., Poutaraud, A., Claudel, P., Mestre, P., Prado, E., et al. (2008) A stress-inducible resveratrol O-methyltransferase involved in the biosynthesis of pterostilbene in grapevine. Plant Physiol., 148, 1630–1639.
7. Dellinger, R. W., Garcia, A. M., and Meyskens, F. L. Jr. (2014) Differences in the glucuronidation of resveratrol and pterostilbene: altered enzyme specificity and potential gender differences. Drug Metab. Pharmacokinet., 29, 112–119.
8. Rimando, A. M., and Suh, N. (2008) Biological/chemopreventive activity of stilbenes and their effect on colon cancer. Planta Med., 74, 1635–1643.
9. Yeo, S. C., Ho, P. C., and Lin, H. S. (2013) Pharmacokinetics of pterostilbene in Sprague-Dawley rats: the impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. Mol. Nutr. Food Res., 57, 1015–1025.
10. Satheesh, M. A., and Pari, L. (2006) The antioxidant role of pterostilbene in streptozotocin-nicotinamide-induced type 2 diabetes mellitus in Wistar rats. J. Pharm. Pharmacol., 58, 1483–1490.
11. Paul, S., Rimando, A. M., Lee, H. J., Ji, Y., Reddy, B. S., et al. (2009) Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells. Cancer Prev. Res. (Phila), 2, 650–657.
12. Dehan, P., Kustermans, G., Guenin, S., Horion, J., Boniver, J., et al. (2009) DNA methylation and cancer diagnosis: new methods and applications. Expert. Rev. Mol. Diagn., 9, 651–657.
13. Einav Nili, G. Y., Saito, Y., Egger, G., and Jones, P. A. (2008) Cancer epigenetics: modifications, screening, and therapy. Annu. Rev. Med., 59, 267–280.
14. Shankar, E., Kanwal, R., Candamo, M., and Gupta, S. (2016) Dietary phytochemicals as epigenetic modifiers in cancer: promise and challenges. Semin. Cancer Biol., 40–41, 82–99.
15. Bruce, K. D., and Cagampang, F. R. (2011) Epigenetic priming of the metabolic syndrome. Toxicol. Mech. Methods, 21, 353–361.
16. Stilling, R. M., and Fischer, A. (2011) The role of histone acetylation in age-associated memory impairment and Alzheimer's disease. Neurobiol. Learn. Mem., 96, 19–26.
17. Gos, M. (2013) Epigenetic mechanisms of gene expression regulation in neurological diseases. Acta Neurobiol. Exp. (Wars.), 73, 19–37.
18. Jaenisch, R., and Bird, A. (2003) Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet., 33, 245–254.
19. Esteller, M. (2008) Epigenetics in cancer. N. Engl. J. Med., 358, 1148–1159.
20. Paluszczak, J., Krajka-Kuzniak, V., and Baer-Dubowska, W. (2009) The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicol. Lett., 192, 119–125.
21. Egger, G., Liang, G., Aparicio, A., and Jones, P. A. (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature, 429, 457–463.
22. Stefanska, B., Salame, P., Bednarek, A., and Fabianowska-Majewska, K. (2012) Comparative effects of retinoic acid, vitamin D and resveratrol alone and in combination with adenosine analogues on methylation and expression of phosphatase and tensin homologue tumour suppressor gene in breast cancer cells. Br. J. Nutr., 107, 781–790.
23. Papoutsis, A. J., Selmin, O. I., Borg, J. L., and Romagnolo, D. F. (2015) Gestational exposure to the AhR agonist 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin induces BRCA-1 promoter hypermethylation and reduces BRCA-1 expression in mammary tissue of rat offspring: preventive effects of resveratrol. Mol. Carcinog., 54, 261–269.
24. Medina-Aguilar, R., Perez-Plasencia, C., Marchat, L. A., Gariglio, P., Garcia, M. J., et al. (2016) Methylation landscape of human breast cancer cells in response to dietary compound resveratrol. PLoS. One, 11, e0157866.
25. Zhu, W., Qin, W., Zhang, K., Rottinghaus, G. E., Chen, Y. C., et al. (2012) Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr. Cancer, 64, 393–400.
26. Lou, X. D., Wang, H. D., Xia, S. J., Skog, S., and Sun, J. (2014) Effects of resveratrol on the expression and DNA methylation of cytokine genes in diabetic rat aortas. Arch. Immunol. Ther. Exp. (Warsz.), 62, 329–340.
27. Kala, R., and Tollefsbol, T. O. (2016) A Novel combinatorial epigenetic therapy using resveratrol and pterostilbene for restoring estrogen receptor-alpha (ERalpha) expression in ERalpha-negative breast cancer cells. PLoS One, 11, e0155057.
28. Farghali, H., Kutinova, C. N., and Lekic, N. (2013) Resveratrol and related compounds as antioxidants with an allosteric mechanism of action in epigenetic drug targets. Physiol. Res., 62, 1–13.
29. Tili, E., Michaille, J. J., Alder, H., Volinia, S., Delmas, D., et al. (2010) Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFbeta signaling pathway in SW480 cells. Biochem. Pharmacol., 15, 2057–2065.
30. Wang, R. H., Zheng, Y., Kim, H. S., Xu, X., Cao, L., et al. (2008) Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol. Cell., 32, 11–20.
31. Papoutsis, A. J., Lamore, S. D., Wondrak, G. T., Selmin, O. I., and Romagnolo, D. F. (2010) Resveratrol prevents epigenetic silencing of BRCA-1 by the aromatic hydrocarbon receptor in human breast cancer cells. J. Nutr., 149, 1607–1614.
32. Kai, L., Samuel, S. K., and Levenson, A. S. (2010) Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int. J. Cancer, 126, 1538–1548.
33. Li, K., Dias, S. J., Rimando, A. M., Dhar, S., Mizuno, C. S., et al. (2013) Pterostilbene acts through metastasis-associated protein 1 to inhibit tumor growth, progression and metastasis in prostate cancer. PLoS One, 8, e57542.
34. Wu, M. L., Li, H., Yu, L. J., Chen, X. Y., Kong, Q. Y., et al. (2014) Short-term resveratrol exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells. PLoS One, 9, e89806.
35. Venturelli, S., Berger, A., Bocker, A., Busch, C., Weiland, T., et al. (2013) Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells. PLoS One, 30, e73097.
36. Ferraresi, A., Phadngam, S., Morani, F., Galetto, A., Alabiso, O., et al. (2017) Resveratrol inhibits IL-6-induced ovarian cancer cell migration through epigenetic up-regulation of autophagy. Mol. Carcinog., 56, 1164–1181.
37. Okawara, M., Katsuki, H., Kurimoto, E., Shibata, H., Kume, T., et al. (2007) Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochem. Pharmacol., 73, 550–560.
38. Heyward, F. D., Gilliam, D., Coleman, M. A., Gavin, C. F., Wang, J., et al. (2016) Obesity weighs down memory through a mechanism involving the neuroepigenetic dysregulation of Sirt1. J. Neurosci., 36, 1324–1335.
39. Chang, Y. C., Lin, C. W., Yu, C. C., Wang, B. Y., Huang, Y. H., et al. (2016) Resveratrol suppresses myofibroblast activity of human buccal mucosal fibroblasts through the epigenetic inhibition of ZEB1 expression. Oncotarget, 7, 12137–12149.
40. Arunachalam, G., Yao, H., Sundar, I. K., Caito, S., and Rahman, I. (2010) SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: role of resveratrol. Biochem. Biophys. Res. Commun., 393, 66–72.
41. Sulaiman, M., Matta, M. J., Sunderesan, N. R., Gupta, M. P., Periasamy, M., et al. (2010) Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol., 298, H833–H843.
42. Kim, D. H., Jung, Y. J., Lee, J. E., Lee, A. S., Kang, K. P., et al. (2011) SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am. J. Physiol. Renal. Physiol., 301, F427–F435.
43. Shakibaei, M., Buhrmann, C., and Mobasheri, A. (2011) Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells. J. Biol. Chem., 286, 11492–11505.
44. Tauriainen, E., Luostarinen, M., Martonen, E., Finckenberg, P., Kovalainen, M., et al. (2011) Distinct effects of calorie restriction and resveratrol on diet-induced obesity and fatty liver formation. J. Nutr. Metab., 2011, 525094.
45. Bruckbauer, A., Zemel, M. B., Thorpe, T., Akula, M. R., Stuckey, A. C., et al. (2012) Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr. Metab. (Lond), 9, 77.
46. Kala, R., Shah, H. N., Martin, S. L., and Tollefsbol, T. O. (2015) Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent gamma-H2AX and telomerase regulation in triple-negative breast cancer. BMC Cancer, 15, 672.
47. Pan, M. H., Lai, C. S., Wu, J. C., and Ho, C. T. (2013) Epigenetic and disease targets by polyphenols. Curr. Pharm. Des., 19, 6156–6185.
48. Filipowicz, W., Bhattacharyya, S. N., and Sonenberg, N. (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet., 9, 102–114.
49. Sapre, N., and Selth, L. A. (2013) Circulating MicroRNAs as biomarkers of prostate cancer: the state of play. Prostate Cancer, 2013, 539680.
50. Venkatadri, R., Muni, T., Iyer, A. K., Yakisich, J. S., and Azad, N. (2016) Role of apoptosis-related miRNAs in resveratrol-induced breast cancer cell death. Cell Death. Dis., 18, e2104.
51. Hagiwara, K., Kosaka, N., Yoshioka, Y., Takahashi, R. U., Takeshita, F., et al. (2012) Stilbene derivatives promote Ago2-dependent tumour-suppressive microRNA activity. Sci. Rep., 2, 314.
52. Leite, K. R., Sousa-Canavez, J. M., Reis, S. T., Tomiyama, A. H., Camara-Lopes, L. H., et al. (2011) Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol. Oncol., 29, 265–269.
53. Dhar, S., Hicks, C., and Levenson, A. S. (2011) Resveratrol and prostate cancer: promising role for microRNAs. Mol. Nutr. Food Res., 55, 1219–1229.
54. Sheth, S., Jajoo, S., Kaur, T., Mukherjea, D., Sheehan, K., et al. (2012) Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PLoS One, 7, e51655.
55. Yang, S., Li, W., Sun, H., Wu, B., Ji, F., et al. (2015) Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo. BMC Cancer, 15, 969.
56. Liu, P., Liang, H., Xia, Q., Li, P., Kong, H., et al. (2013) Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR-21 regulation of BCL-2 expression. Clin. Transl. Oncol., 15, 741–746.
57. Bae, S., Lee, E. M., Cha, H. J., Kim, K., Yoon, Y., et al. (2011) Resveratrol alters microRNA expression profiles in A549 human non-small cell lung cancer cells. Mol. Cells, 32, 243–249.
58. Ren, X., Bai, X., Zhang, X., Li, Z., Tang, L., et al. (2015) Quantitative nuclear proteomics identifies that miR-137-mediated EZH2 reduction regulates resveratrol-induced apoptosis of neuroblastoma cells. Mol. Cell Proteomics, 14, 316–328.
59. Azimi, A., Hagh, M. F., Talebi, M., Yousefi, B., Hossein pour feizi, A. A., et al. (2015) Time-and concentration-dependent effects of resveratrol on miR 15a and miR16-1 expression and apoptosis in the CCRF-CEM acute lymphoblastic leukemia cell line. Asian Pac. J. Cancer Prev, 16, 6463–6468.
60. Fan, Y., Liu, L., Fang, K., Huang, T., Wan, L., et al. (2016) Resveratrol ameliorates cardiac hypertrophy by down-regulation of miR-155 through activation of breast cancer type 1 susceptibility protein. J. Am. Heart Assoc., 5, e002648.
61. Gracia, A., Miranda, J., Fernandez-Quintela, A., Eseberri, I., Garcia-Lacarte, M., et al. (2016) Involvement of miR-539-5p in the inhibition of de novo lipogenesis induced by resveratrol in white adipose tissue. Food Funct., 7, 1680–1688.
62. Su, C. M., Lee, W. H., Wu, A. T., Lin, Y. K., Wang, L. S., et al. (2015) Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition. J. Nutr. Biochem., 26, 675–685.
63. Mak, K. K., Wu, A. T., Lee, W. H., Chang, T. C., Chiou, J. F., et al. (2013) Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells within tumor microenvironment and metastasis via modulating NF-kappaB/microRNA 448 circuit. Mol. Nutr. Food Res., 57, 1123–1134.
64. Huynh, T. T., Lin, C. M., Lee, W. H., Wu, A. T., Lin, Y. K., et al. S. (2015) Pterostilbene suppressed irradiation-resistant glioma stem cells by modulating GRP78/miR-205 axis. J. Nutr. Biochem., 26, 466–475.
65. Wang, W., Ding, X. Q., Gu, T. T., Song, L., Li, J. M., et al. (2015) Pterostilbene and allopurinol reduce fructose-induced podocyte oxidative stress and inflammation via microRNA-377. Free Radic. Biol. Med., 83, 214–226.
66. Dhar, S., Kumar, A., Rimando, A. M., Zhang, X., and Levenson, A. S. (2015) Resveratrol and pterostilbene epigenetically restore PTEN expression by targeting oncomiRs of the miR-17 family in prostate cancer. Oncotarget, 6, 27214–27226.